Please login to the form below

Not currently logged in
Email:
Password:

Chimerix

This page shows the latest Chimerix news and features for those working in and with pharma, biotech and healthcare.

Merck says drug for CMV in transplant patients hits targets

Merck says drug for CMV in transplant patients hits targets

The company's good news comes after another CMV drug developer - Chimerix - reported that its brincidofovir CMV candidate failed a pair of pivotal trials.

Latest news

  • Chimerix hit as lead drug brincidofovir flunks trial Chimerix hit as lead drug brincidofovir flunks trial

    Patients in the brincidofovir arm also showed an increase in mortality compared to the control arm, but the increase was not statistically significant, according to Chimerix. ... Both GVHD and use of corticosteroids are risk factors for 'late' CMV

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Pharma deals during July 2012 Pharma deals during July 2012

    Anti-infective deals. A similar size to the Genmab deal at $168m is the agreement between Chimerix, a US based private company developing antiviral therapies and Merck &Co. ... 178. Chimerix / Merck &Co. Licence. Lipid antiviral conjugate in phase 1 for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Former Glaxo CEO Ernest Mario to chair Chimerix Former Glaxo CEO Ernest Mario to chair Chimerix

    Chimerix has appointed pharma veteran and former CEO of Glaxo Holdings Dr Ernest Mario as the company's new chairman. ... Dr Mario replaces Dr James Niedel, who will remain as a member of the board at Chimerix.

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Understanding behaviour change: A Porterhouse Insights specialism
...
Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...